Quick Answer
Biodexa Pharmaceuticals Plc reported Research And Development Expense of $3.96 million for the year ending 2025.
- Biodexa Pharmaceuticals Plc showed a decrease of -27.1% in Research And Development Expense from 2024 to 2025.
- This data is from Biodexa Pharmaceuticals Plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Biodexa Pharmaceuticals Plc's Research And Development Expense has declined by 54.5%.
- Historical annual values: Fiscal year 2025: $3.96 million | Fiscal year 2024: $5.44 million | Fiscal year 2023: $4.07 million | Fiscal year 2022: $5.11 million | Fiscal year 2021: $4.65 million | Fiscal year 2020: $6.07 million | Fiscal year 2019: $7.84 million | Fiscal year 2018: $9.36 million | Fiscal year 2017: $8.33 million | Fiscal year 2016: $7.73 million | Fiscal year 2015: $8.71 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: